Phase2 Trial of Carboplatin-Paclitaxel bi-weekly and Bevacizumab combination therapy for Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer
Phase 2
- Conditions
- onsquamous Non-Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000006525
- Lead Sponsor
- Shimane University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Exclusion Criteria
1) Squamous cell carcinoma. 2) Patients with double cancer. 3) Plan on Concurrent Radiotherapy. 4) Patients with active severe infections. 5) Patients with brain metastasis. 6) History of hemoptysis. 7) Cavity in tumor. 8) Have a bleeding diathesis. 9) Concurrent use of steroid therapy. 10) Use of flucytosine. 11) History of thrombosis. 12) Patients with massive uncontrolled pleural or pericardial effusion ,or ascites. 13) Patients with active severe comorbidity disease. 14) Patients with serious drug allergic reactions. 15) Patients with active concomitant pregnancy. 16) Inappropriate patients for this study judged by the physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate with Response Evaluation Criteria In Solid Tumors (RECIST) criteria
- Secondary Outcome Measures
Name Time Method 1.Overall Survival 2.Progression-free survival 3.Time to treatment failure 4.Quality of Life(QOL) survey with FACT-L 5.Evaluation of comorbidity and function with CCI and VES-13 survey 6.Safety(adverse outcome) 7.Blood levels of MMP-9 , PIGF and sVEGFR 8.Analysis of polymorphisms in the VEGF gene(VEGF-A/VEGF-R2)